VTGN
NASD Vistagen Therapeutics, Inc.$0.2148 ↑ +0.0000 (+0.00%) Trading Up from the previous close of $0.2148, $0.0102 below the day’s high of $0.2250
- YTD change
- -67.55%
- vs 20-day SMA
- -18.90%
- vs 200-day SMA
- -55.32%
Price ranges
Price & Performance
-0.36 (-62.71%) / 6M
Signals & Sentiment
Momentum, market sentiment, and recent alerts
- The stock is 99.8% away from all-time highs of $135.0000
- VTGN is down 68% since the beginning of the year
- VTGN is down 95% over the past 12 months
- VTGN is down 12% over the past 1 month
- 8% of all VTGN investors are betting against VTGN
VTGN reads poor: price sits below both the 20- and 200-day averages, the 12-month move is -94.5%.
- Previous minute
- -$0.0044
- Last hour
- -$0.0065
- Last 5 days
- -18.39%
- vs 8-day SMA
- -15.49%
Financial Strength
Earnings, valuation, and balance sheet
Earnings
Valuation
Balance sheet & scale
Company & Peers
Company profile and competitor comparison
Company profile
Vistagen Therapeutics, Inc. is a late clinical-stage biopharmaceutical company, which engages in developing and commercializing medication and treatment for anxiety, depression, and other central nervous system disorders. Its product portfolio includes Fasedienol (PH94B) nasal spray for social anxiety disorder, Itruvone (PH10) nasal spray for depression disorders, AV-101 oral NMDR glycine site antagonist for depression and neurological disorders, PH15 acute treatment for improvement of cognition, PH80 acute management of vasomotor symptoms due to menopause, and PH284 acute management of Wasting syndrome (Cachexia). The company was founded by H. Ralph Snodgrass and Gordon Keller on May 26, 1998 and is headquartered in South San Francisco, CA.
You looked up one stock
Trade Ideas watches them all
Real-time scanning and AI-generated signals across the entire market.
Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.
